The UK and US have announced a major commercial pact that will preserve no duties on British drug products going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to increase funding on medicines through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial goods will be held at nothing for a period of three years.
This development is in response to recent threats to hike import taxes on patented drug products, with increases discussed reaching one hundred percent.
"This arrangement between the Britain reinforces the global environment for new treatments and brings long-overdue fairness to transatlantic drug exports," a release noted.
Economic Importance
Pharmaceuticals represent one of the Britain's largest export categories to the US, which is clearly the primary market for major British pharmaceutical firms.
Trade data indicate that in the 12 months leading up to last September, the UK exported medicines valued at £11.1bn to the US. This value represented a significant portion of total UK exports in that span.
"This agreement secures jobs, stimulates capital expenditure and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Detailed British Pledges
The agreement involves several notable pledges from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to double overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage manufacturers must return to the NHS to prevent overspending will be capped at 15%. In the past, refunds exceeded twenty percent.
Broader Context
The pact takes place against a protracted row between the drug companies and the British authorities over drug pricing and approval rates.
This friction were intensified by assertions that American patients were paying several times more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or cancelled, while multi-billion-dollar investments have been announced toward US facilities.
One official stated that the NHS must spend more on medicines, noting that its spending on drugs had shrunk as a proportion of its overall budget over the last ten years.
